July 22, 2017 3:50 AM ET


Company Overview of R-Pharm-US LLC

Company Overview

R-Pharm-US LLC, a specialty pharmaceutical company, develops and commercializes medicines for the treatment of cancer and chronic immune diseases. The company’s portfolio of product includes IXEMPRA, a chemotherapy agent for metastatic breast cancer; molecules for immunology and oncology indications; and olokizumab, an IL-6 for rheumatoid arthritis and other immunologic conditions. Its portfolio also includes RPH-104, a recombinant heterodimer nanoprotein; RPH-203, an osteoprotegrin-IgG1 fusion protein for the treatment of tumor-related bone lytic lesions, giant cell bone tumors, osteoporosis, etc.; and RPH-001 and RPH-002 for oncology biosimilar MABs. The company was founded in 2014 and is ...

P.O. Box 3096

Princeton, NJ 08543

United States

Founded in 2014



Key Executives for R-Pharm-US LLC

Chief Executive Officer and President
Age: 53
President and Chief Business Officer
Head of Worldwide Commercial Operations
Vice President of Global Supply Chain and Manufacturing
Vice President of Sales and Market Access
Age: 60
Compensation as of Fiscal Year 2017.

R-Pharm-US LLC Key Developments

Midatech Pharma US Announces Partnership with R-Pharm US LLC to Co-Promote Zuplenz(R) (Ondansetron) Oral Soluble Film and Oravig(R) (Miconazole) Orally-Dissolving Buccal Tablet

Midatech Pharma announced that its US subsidiary, Midatech Pharma US, has finalised a co-promotion agreement with R-Pharm US LLC providing additional reach and frequency for the promotion of Zuplenz and Oravig to oncology accounts across the US. Under the terms of the agreement, R-Pharm will promote Zuplenz and Oravig in accounts that are not currently in the Midatech Pharma US call universe as well as provide additional promotion in accounts where Midatech currently markets its oncology supportive care product portfolio.

Camurus Signs Distribution Agreement with R-PHARM US

Camurus announced that they have granted R-PHARM US (Princeton, NJ) the exclusive license and distribution rights for episil® oral liquid in the US.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact R-Pharm-US LLC, please visit www.rpharm-us.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.